Alnylam Pharmaceuticals Cuts Revenue Guidance Amid Market Headwinds
Alnylam Pharmaceuticals (ALNY) experienced a significant drop of over 25% on Thursday, reaching its lowest point in the past year. The decline followed the company's announcement during Q2 earnings that it is revising down its full-year product revenue guidance due to challenges within the ATTR-CM therapies market. The reduced outlook reflects ongoing difficulties Alnylam faces with competition and adoption rates for its treatments targeting transthyretin amyloid cardiomyopathy (ATTR-CM). This has raised concerns among investors about future performance, leading to a sharp sell-off in shares. The stock's drop highlights investor sensitivity to guidance changes from biotech firms. Alnylam’s revised revenue expectations have sparked broader discussions around the sustainability of its market position and pricing power for key therapies.
Tickers: $ALNY